Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NASDAQ:STOK NASDAQ:TECX NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$16.19+0.9%$15.08$7.28▼$16.88$2.10B1.441.06 million shs204,294 shsSTOKStoke Therapeutics$32.82-0.4%$34.46$8.51▼$40.22$2.04B1.2723,108 shs65,395 shsTECXTectonic Therapeutic$28.97-1.3%$29.24$14.39▼$36.03$547.12M3.27322,457 shs28,952 shsZYMEZymeworks$27.47+2.9%$25.47$10.86▼$29.75$2.03B1.2701,987 shs91,212 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+4.50%0.00%+2.75%+10.01%+94.19%STOKStoke Therapeutics-0.36%-1.11%+0.67%+3.00%+239.79%TECXTectonic Therapeutic+1.03%+7.94%-3.80%+26.44%+37.26%ZYMEZymeworks+0.26%-4.51%+3.41%+15.45%+2,667,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$16.19+0.9%$15.08$7.28▼$16.88$2.10B1.441.06 million shs204,294 shsSTOKStoke Therapeutics$32.82-0.4%$34.46$8.51▼$40.22$2.04B1.2723,108 shs65,395 shsTECXTectonic Therapeutic$28.97-1.3%$29.24$14.39▼$36.03$547.12M3.27322,457 shs28,952 shsZYMEZymeworks$27.47+2.9%$25.47$10.86▼$29.75$2.03B1.2701,987 shs91,212 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+4.50%0.00%+2.75%+10.01%+94.19%STOKStoke Therapeutics-0.36%-1.11%+0.67%+3.00%+239.79%TECXTectonic Therapeutic+1.03%+7.94%-3.80%+26.44%+37.26%ZYMEZymeworks+0.26%-4.51%+3.41%+15.45%+2,667,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.50Moderate Buy$17.256.54% UpsideSTOKStoke Therapeutics 2.92Moderate Buy$41.8327.48% UpsideTECXTectonic Therapeutic 2.88Moderate Buy$80.57178.15% UpsideZYMEZymeworks 2.92Moderate Buy$37.8937.95% UpsideCurrent Analyst Ratings BreakdownLatest TECX, AUPH, ZYME, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)4/27/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026TECXTectonic Therapeutic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ZYMEZymeworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026TECXTectonic Therapeutic Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.004/10/2026STOKStoke Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/20/2026STOKStoke Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $60.003/19/2026STOKStoke Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.003/18/2026STOKStoke Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.003/17/2026STOKStoke Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $38.003/17/2026STOKStoke Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$283.05M7.43$1.04 per share15.56$4.41 per share3.67STOKStoke Therapeutics$184.42M11.08N/AN/A$6.17 per share5.32TECXTectonic TherapeuticN/AN/AN/AN/A$13.43 per shareN/AZYMEZymeworks$105.96M19.12N/AN/A$3.59 per share7.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$287.20M$2.087.7820.24N/A101.46%27.47%19.61%5/11/2026 (Estimated)STOKStoke Therapeutics-$6.89M-$0.12N/AN/AN/A-3.73%-2.05%-1.75%5/7/2026 (Estimated)TECXTectonic Therapeutic-$74.15M-$4.05N/AN/AN/AN/A-26.88%-25.83%5/7/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.08N/A39.80N/A-76.56%-26.00%-20.57%5/7/2026 (Estimated)Latest TECX, AUPH, ZYME, and STOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026AUPHAurinia Pharmaceuticals$0.18N/AN/AN/A$76.98 millionN/A5/7/2026Q1 2026STOKStoke Therapeutics-$0.80N/AN/AN/A$6.48 millionN/A5/7/2026Q1 2026TECXTectonic Therapeutic-$1.16N/AN/AN/AN/AN/A5/7/2026Q1 2026ZYMEZymeworks-$0.10N/AN/AN/A$24.38 millionN/A3/16/2026Q4 2025STOKStoke TherapeuticsN/A-$0.97N/A-$0.97N/A$1.40 million3/2/2026Q4 2025ZYMEZymeworks-$0.35-$0.55-$0.20-$0.55$21.78 million$2.52 million2/26/2026Q4 2025AUPHAurinia Pharmaceuticals$0.21$1.53+$1.32$1.53$74.70 million$77.11 million2/26/2026Q4 2025TECXTectonic Therapeutic-$1.11-$1.03+$0.08-$1.03N/AN/A2/14/2026Q4 2025ZYMEZymeworksN/A-$0.55N/A-$0.55N/A$2.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.095.254.76STOKStoke TherapeuticsN/A5.285.28TECXTectonic TherapeuticN/A26.6226.63ZYMEZymeworksN/A5.885.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%STOKStoke TherapeuticsN/ATECXTectonic Therapeutic62.63%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%STOKStoke Therapeutics9.50%TECXTectonic Therapeutic39.80%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300129.94 million114.09 millionOptionableSTOKStoke Therapeutics10062.27 million56.36 millionOptionableTECXTectonic Therapeutic12018.85 million11.35 millionN/AZYMEZymeworks46073.75 million49.04 millionN/ATECX, AUPH, ZYME, and STOK HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Invests $1.97 Million in Zymeworks Inc. $ZYMEMay 5 at 4:58 AM | marketbeat.comKornitzer Capital Management Inc. KS Takes $2.34 Million Position in Zymeworks Inc. $ZYMEMay 3 at 7:02 AM | marketbeat.comBMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecificApril 30, 2026 | fiercebiotech.comFZymeworks (ZYME) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comZymeworks (NASDAQ:ZYME) Raised to Strong-Buy at Truist FinancialApril 28, 2026 | marketbeat.comZymeworks (NASDAQ:ZYME) Hits New 52-Week High - Time to Buy?April 28, 2026 | marketbeat.comZymeworks Highlights Royalty-Fueled Pivot at Bloom Burton, Eyes Multibillion-Dollar ZiiheraApril 26, 2026 | marketbeat.comZymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 23, 2026 | marketbeat.comZymeworks (NASDAQ:ZYME) Hits New 1-Year High - What's Next?April 22, 2026 | marketbeat.comZymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026April 21, 2026 | globenewswire.comAACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new dataApril 21, 2026 | biospace.comBZymeworks Inc.: Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformApril 17, 2026 | finanznachrichten.deZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformApril 17, 2026 | globenewswire.comHow Investors May Respond To Zymeworks (ZYME) Hiring EcoR1 Executives To Lead R&D And DealsApril 17, 2026 | finance.yahoo.comZymeworks Sets May 7 Date to Unveil Q1 2026 Results and Pipeline UpdateApril 16, 2026 | tipranks.comZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026April 16, 2026 | financialpost.comFZymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026April 16, 2026 | globenewswire.comJPMorgan Chase & Co. Cuts Stock Position in Zymeworks Inc. $ZYMEApril 13, 2026 | marketbeat.comZymeworks announces leadership appointmentsApril 9, 2026 | thepharmaletter.comTZymeworks Announces Additional Leadership Appointments to Advance Next Phase of GrowthApril 9, 2026 | financialpost.comFZymeworks Announces Additional Leadership Appointments to Advance Next Phase of GrowthApril 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTECX, AUPH, ZYME, and STOK Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$16.19 +0.15 (+0.94%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Stoke Therapeutics NASDAQ:STOK$32.82 -0.15 (-0.44%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Tectonic Therapeutic NASDAQ:TECX$28.97 -0.39 (-1.34%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Zymeworks NASDAQ:ZYME$27.46 +0.79 (+2.94%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
